Skip to content

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03048279
Enrollment
1500
Registered
2017-02-09
Start date
2001-09-05
Completion date
2026-09-01
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Endocrine Neoplasia Syndromes

Keywords

Multiple Endocrine Neoplasia Syndromes, MEN1, MEN2, Relatives, Database, Questionnaires, Surveys

Brief summary

Objectives: To contribute new and prospective data to our existing database library for patients with MEN1 and MEN2 at The University of Texas M.D. Anderson Cancer Center.

Detailed description

Previously followed MEN1 and MEN2 patients at M.D. Anderson Cancer Center will be mailed an introductory letter and a "consent to be contacted" form to determine whether they are interested in participating in the study. New MEN1 and MEN2 patients seen in clinic at M.D. Anderson Cancer Center will be asked if they wish to learn more about this study. Interested patients will also be asked to distribute the introductory letter and consent to be contacted form to their blood relatives. Printed materials regarding this study will only be mailed to non-MDACC individuals with the expressed written or verbal permission from a consenting MDACC patient. All interested individuals will return the signed "consent to be contacted" form to the PI. Consented individuals will be interviewed by phone and/or mail to obtain updated family and medical history specific to their diagnosis of either MEN1 or MEN2. To verify accuracy of medical data collected, all non-MDACC participants will be asked if they consent to have their off-site medical records released to us for review. There will be no treatment or collection of blood or tissue in this study. Although this study presents minimal risk to participants, participant consent will be obtained due to the need to obtain permission to make contact with patients and their families. Approximately 1500 patients and their relatives will be included in this study. This will be done on an inpatient and outpatient basis.

Interventions

BEHAVIORALQuestionnaires

Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2. Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

1. Registered MDACC patients diagnosed with MEN1 or MEN2. 2. Close relatives of registered MDACC MEN patients.

Exclusion criteria

1\. Individuals who are either non-MDACC registered patients or do not have a close relative who is an MEN patient registered at MDACC.

Design outcomes

Primary

MeasureTime frame
Contribution of New and Prospective Data to Existing Database Library for Patients with MEN1 and MEN2 by Completion of Health Questionnaires25 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORNancy D. Perrier, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026